Latest Healthcare News

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.

BlinkLab’s smartphone-based Dx1 autism screening technology has been selected for Morocco’s government-funded national early screening program, marking a major milestone in digital health adoption and autism care.

Terra Critical Minerals has expanded its footprint in New South Wales with a new exploration license at the historic Silent Grove tin project, revealing significant historical tin mineralisation up to 5.21%. The company plans modern exploration to unlock this critical mineral’s potential amid rising global demand.

Cyclopharm has secured a significant multi-site agreement with the University of Pennsylvania Health System, marking a major step in its US expansion with installations across 11 clinical locations.

Cleo Diagnostics has expanded its ovarian cancer biomarker panel from five to eight markers, enhancing test reliability and gearing up for FDA submission. A manufacturing deal is imminent, setting the stage for commercial rollout.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Enlitic has secured a $1.5 million contract to migrate over 71 million clinical files for Penn Medicine Doylestown Health, reinforcing its foothold in the US healthcare IT sector.

Synlait confirms the imminent sale of its North Island assets to Abbott for NZ$307 million, aiming to reset its balance sheet amid a challenging half-year result. The company unveils a recovery roadmap focused on stabilising and scaling its core operations.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.